Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Cancers|March 13, 2025
Baseline Characteristics of Participants in the Alberta Cancer Exercise Hybrid Effectiveness-Implementation Study: A Wake-Up Call for ActionMargaret L McNeely, Shirin M Shallwani, Tanya Williamson, et al.
The Oncologist|June 21, 2019
Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 TrialVéronique Diéras, Nadia Harbeck, Anil Abraham Joy, et al.
Cancers|September 13, 2025
Role of Qualified Exercise Professionals in Medical Clearance for Exercise: Alberta Cancer Exercise Hybrid Effectiveness-Implementation StudyMargaret L McNeely, Tanya Williamson, Shirin M Shallwani, et al.
Current Oncology (Toronto, Ont.)|October 28, 2025
Baseline Characteristics of Individuals with Metastatic Cancer Enrolled in the Alberta Cancer Exercise Study and 12-Week Findings for Symptom-Related and Physical Fitness MeasuresShirin M Shallwani, S Nicole Culos-Reed, Kerry S Courneya, et al.
Current Oncology (Toronto, Ont.)|June 2, 2021
Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate CancerMegan M Tu, Mark Clemons, Carol Stober, et al.
Breast Cancer Research and Treatment|May 26, 2019
Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT)Bassam Basulaiman, Arif Ali Awan, Dean Fergusson, et al.
Plos One|February 4, 2021
Optimising weight-loss interventions in cancer patients-A systematic review and network meta-analysisNathalie LeVasseur, Wei Cheng, Sasha Mazzarello, et al.
Journal of Bone Oncology|September 27, 2021
Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michelle Liu, Carol Stober, et al.
BMJ Open|September 15, 2019
Community-based exercise for health promotion and secondary cancer prevention in Canada: protocol for a hybrid effectiveness-implementation studyMargaret L McNeely, Christopher Sellar, Tanya Williamson, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2020
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michael Ong, Carol Stober, et al.
Pageof 9